Sekisui has announced the decision to invest £14.4 million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022.
It is fantastic to see the investment going into Sekisui’s site in Maidstone, Kent and we would like to pass our congratulations to the whole team! As a Kent based company ourselves, we can really appreciate the significance of this investment to the local community, as well as to the UK biotech sector.
This investment follows the investment of $1.9 million in its new Bioprocess Innovation Centre, completed in October 2019, and is part of a long-term investment strategy to grow its share of the microbial biopharma CDMO market.
The facility expansion and cGMP upgrades will enable Sekisui to take on drug substance contract manufacturing for programs entering the clinical trial phase. The new cGMP certified microbial fermentation and purification suites will accommodate production scales up to 1,000L, complementing its existing capabilities which range from 20L to 5,000L fermentation scale.
